In patients with venous thromboembolism (VTE) who are candidates for oral anticoagulation, apixaban results in fewer hospitalizations for recurrence and less major bleeding than rivaroxaban or ...

For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban. Data remain inconclusive regarding ...

Across all CKD stages, the patients treated with apixaban had a lower incidence of recurrent VTE compared with the patients treated with warfarin (stage 5/ESRD, 7.7 vs 11.6; stage 4, 5.8 vs 7.8 ...

For patients with non-valvular atrial fibrillation, study results showed treatment with apixaban was associated with a lower risk for chronic kidney disease progression compared with warfarin.

The treatment advantages of apixaban, compared with warfarin, seen in the overall AUGUSTUS results, first reported in March 2019, "were consistent" with the benefits seen in the subgroup of ...

The blood thinner apixaban (Eliquis) is safe and effective in stroke patients and may present fewer risks than warfarin, according to a secondary analysis. The drug is associated with less ...

Apixaban also had large reductions in VTE (32%) relative to warfarin. 1 A subgroup analysis presented alongside the main study found that apixaban’s benefits relative to LMWH held up across ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- Apixaban (Eliquis) may be better than warfarin (Coumadin) for lowering the incidence of systemic embolism ...

Venous thromboembolism artery. Patients with CKD stage 3 or 4 and atrial fibrillation treated with apixaban vs warfarin have a 36% decreased risk of stroke or venous thromboembolism, a meta ...

Researchers studied three common DOACs — dabigatran, rivaroxaban and apixaban — and compared them with warfarin in patients with and without atrial fibrillation. They used data from two United ...